About US
Contact us
-
With the competition struggling, Pfizer's COVID vaccine sales could hit $24B this year: analystMessenger RNA COVID-19 vaccines are sailing along as viral vector shots encounter setback after setback. How will the recent headlinesaffect vaccine sales in 2021? In his weekly notes to investors, B2021/4/19
-
Lower Libtayo's price before Chinese PD-1s do, says analyst in open letter to Regeneron CEORegeneron and partner Sanofi recently snagged an FDA nod for Libtayo in the large and lucrative indication of newly diagnosed non-small cell lung cancer (NSCLC). And one analyst is already asking the2021/4/19
-
Moderna eyes beefed-up vaccine production with the help of U.S.-brokered manufacturing talks: reportThe feds already had a hand in Merck and Johnson & Johnson's "wartime" COVID-19 production pact. Now, Moderna is reportedly in government-brokered talks with a potential manufacturing partner. Mo2021/4/16
-
Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med ActemraNovartis wasn’t kidding when it said it wanted to help with the global COVID-19 fight earlier this year. The company racked up back-to-back manufacturing pacts with Pfizer-BioNTech and CureVac,and, n2021/4/16
-
With crucial EU launch rolling, Amarin's Thero hands CEO baton to new European commercial chiefJust as Amarin’s heart drug Vascepa begins its make-or-break European launch, the company is changing leadership at the top. The move adds uncertainty to the mix, one analyst said, and tones down the2021/4/14
-
Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot casesAfter drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials arecalling for an immediate pauseto the rollout. Since the vac2021/4/14
-
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reportsIndia is one of the world's biggest manufacturers of drugs and vaccines, but that hasn't made it immune to COVID-19 supply instability. Now, the government is locking up at least one treatmentfor its2021/4/13
-
FDA joins Europe in probing rare blood clots after Johnson & Johnson's COVID-19 vaccineDrug regulators in Europe last week flagged rare but “serious” cases of blood clotsin people who had receivedJohnson & Johnson’s COVID-19 vaccine.But it’s not just European regulatorstaking a clo2021/4/13
-
FibroGen admits to messing with roxadustat safety data, upending hopes for the AZ-partnered anemia drugIn a stunning revelation, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is. The late-Tuesday announcement sent FibroGen shares tumbling and pr2021/4/9
-
J&J scores backing from Chamber of Commerce, PhRMA and more in Supreme Court appeal of $2.1B talc verdictJohnson & Johnson has ginned upmajor support in its quest to challenge a $2.1 billionverdict over claims that its talc-based powders cause cancer. The U.S. Chamber of Commerce and other business2021/4/9